#ImmVira #EX104 #EX105

ImmVira's Revolutionary Engineered Exosomes Launch into the Global Market

In the realm of advanced biotechnology, ImmVira Group has taken a monumental step by securing the International Nomenclature of Cosmetic Ingredients (INCI) designation for its novel engineered exosome products. Specifically, MVR-EX104 and MVR-EX105 are designed for treating hair loss due to alopecia and targeting localized fat accumulation, respectively. This recent achievement places ImmVira at the forefront of the aesthetics sector, addressing a rapidly growing market that is expected to exceed $280 billion by 2033, as highlighted by market research from Frost and Sullivan.

The company's innovative platform, OVPENS technology, enables the creation of engineered exosome products that hold significant potential for both cosmetic applications and clinical therapeutics. Notably, this advancement follows the INCI recognition for MVR-EX103, another engineered product aimed at skin-related conditions. These exosomes not only signify a technological advantage but also represent a strategic approach to meet the rising demand for effective solutions in the booming market of aging-related health concerns.

The Importance of INCI Designation

The INCI designation is a pivotal benchmark in the cosmetic industry, allowing products to access international markets with a predetermined standard that ensures ingredient transparency and safety for consumers. This universal